iBio Announces FY25 EPS of $1.75 Compared to ($6.50) in the Previous Year
Financial Performance: iBio reported FY25 revenue of $400k, a significant increase from $225k the previous year, indicating strong growth and progress in their corporate strategy.
Pipeline Development: The company advanced its preclinical portfolio in cardiometabolic diseases and obesity, introducing innovative products like IBIO-610 and IBIO-600, along with a bispecific antibody program and a novel amylin receptor antibody through collaboration with AstralBio.
Corporate Achievements: iBio successfully transferred its stock listing to Nasdaq, strengthened its balance sheet, and added experienced leaders to its Board and management team, positioning the company for long-term growth.
Commitment to Innovation: iBio remains dedicated to delivering transformative therapies to patients while creating sustainable value for shareholders, as recognized by life sciences investors in their recent funding round.
Trade with 70% Backtested Accuracy
Analyst Views on IBIO
About IBIO
About the author
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
iBio Reveals Promising Non-Human Primate Data for IBIO-610, an Activin E Antibody with Significant Potential for Targeted Weight Loss and Maintenance
IBIO-610 Overview: iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, showing significant fat-selective weight loss and prevention of weight regain in a diet-induced obesity mouse model.
Extended Half-Life Findings: New data from non-human primate studies indicates an extended half-life of 33.2 days, with a predicted human half-life of up to 100 days, suggesting the possibility of dosing only twice a year.
Therapeutic Potential: The unique mechanism of action of IBIO-610 may provide a more comprehensive treatment for obesity and cardiometabolic diseases, addressing gaps left by current GLP-1 therapies.
Presentation at ObesityWeek: The findings will be presented at ObesityWeek 2025, highlighting the potential of IBIO-610 to improve patient experience with less frequent dosing and reduced side effects compared to existing treatments.
